Company Overview of Hutchison MediPharma Limited
Hutchison MediPharma Limited, a drug research and development company, engages in the discovery, development, and commercialization of therapeutics for oncology and autoimmune diseases in North America, Europe, Australia, and Greater China. Its portfolio includes HMPL-004, an oral botanical product that acts on multiple targets in the pathogenesis of inflammatory bowel disease; Sulfatinib/HMPL-012, a small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor (VEGF) and fibroblast growth factor receptors; and Fruquintinib/HMPL-013, a small molecule compound that selectively inhibits VEGF receptors; Epitinib/HMPL-813, an orally acti...
720 Cai Lun Road
Zhangjiang Hi-Tech Park
Founded in 2002
Key Executives for Hutchison MediPharma Limited
Interim Chief Executive Officer and Director
Executive Vice President of Drug Research
Senior Vice President of Pharmaceutical Sciences
Executive Vice President of Non Clinical Development and Project Operations
Head of Oncology Research and Vice President
Compensation as of Fiscal Year 2014.
Hutchison MediPharma Limited Key Developments
Hutchison Medipharma Limited Completes Patient Enrolment in Phase II Clinical Trial of Fruquintinib in Colorectal Cancer in China
Aug 21 14
Hutchison MediPharma Limited has completed patient enrolment in a Phase II clinical trial of fruquintinib in colorectal cancer in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors. This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with metastatic CRC, who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in early 2015. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib.
Hutchison MediPharma Limited Starts Phase I Clinical Trial with HMPL-523
Jun 18 14
Hutchison China MediTech Limited announced that Hutchison MediPharma Limited has initiated the first-in-human Phase I clinical trial of HMPL-523 in Australia. HMPL-523 is a novel, highly selective and potent small molecule inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. HMPL-523 is HMP's second active immunology programme in clinical development. The first drug dose was administered on 17 June 2014. As one of the major cellular components of the immune system, B-cells play pivotal roles in autoimmune diseases. Targeted B-cell receptor signalling therapy has been proven to be clinically effective for the treatment of rheumatoid arthritis ("RA") and B-cell malignancies, leading to scientific and commercial success. Syk is an essential enzyme involved in B-cell receptor signalling pathway and a novel target for investigational therapies in immunology and oncology. HMPL-523 is being developed as an oral formulation for the treatment of autoimmune diseases such as RA and lupus. In preclinical studies, HMPL-523 demonstrated superior potency and kinase selectivity, a reversal of the progression of joint inflammation and bone erosion along with a reduced production of multiple pro-inflammatory cytokines, as well as a favourable safety margin in both rodent and non-rodent toxicology studies. The first-in-human trial aims to establish the safety profile of HMPL-523. This randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of HMPL-523 will be conducted in healthy volunteers. Initial results are expected around the end of 2014.
Hutchison MediPharma Limited Announces Initiation of Fruquintinib Phase II Study in Non-Small Cell Lung Cancer
Jun 5 14
Hutchison China MediTech Limited announced that Hutchison MediPharma Limited (HMP) has initiated a Phase II clinical trial in non-small cell lung cancer ("NSCLC") patients in China for fruquintinib (HMPL-013), its investigational small molecule agent that is designed to selectively inhibit vascular endothelial growth factor receptors ("VEGFR"). Preparations and patient screening began earlier this year, with the first patient dosed on 4 June 2014. This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept ("POC") Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy. This trial is to evaluate the efficacy and safety of fruquintinib versus placebo in NSCLC patients. All patients will receive best supportive care. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. Approximately 90 patients will be enrolled, with top-line results expected in 2015. Fruquintinib is designed to selectively inhibit VEGF receptors, including VEGFR1, 2, and 3. In the first-in-human Phase I clinical trial, 40 late-stage cancer patients were treated with fruquintinib. Based on the Phase I data, the first POC Phase II study was initiated on 2 April 2014, which was a randomized, double-blind, placebo-controlled, multi-centre Phase II clinical trial targeted at treating patients with locally advanced or metastatic colorectal cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|